The Chinese National Development and Reform Commission opens a broad investigation into pharmaceutical pricing

Earlier this month, China’s National Development and Reform Commission (“NDRC”) announced that it is conducting a wide-ranging probe into the costs and prices of pharmaceutical products sold by more than 60 multinational and domestic companies. NDRC has broad powers to enforce China’s Price Law, including setting the Maximum Retail Price (“MRP”) for drugs and vaccines that are covered by the National Reimbursement Drug List (“covered drugs”). [1] NDRC also enforces the price- related provisions of China’s Anti-Monopoly Law (“AML”), such as the AML’s prohibitions against resale price maintenance, price discrimination, and the charging by “dominant” companies of “unfairly high prices.” This client alert provides an overview of the NDRC’s investigation and a brief discussion of its potential

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Shanghai)
  • Covington & Burling (Washington)
  • Covington & Burling (Beijing)
  • Covington & Burling (Beijing)

Quotation

Daniel L. Spiegel, John D. Graubert, Weishi Li, James J. O'Connell, Timothy Stratford, Yan Luo, The Chinese National Development and Reform Commission opens a broad investigation into pharmaceutical pricing , 10 July 2013, e-Competitions July 2013, Art. N° 95790

Visites 25

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues